Compounded Sema Injectable denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Compounded Semaglutide as Experimental

Cigna's "experimental" or "investigational" denial for compounded semaglutide injectable reflects Cigna's position that compounded formulations of semaglutide — those prepared by a compounding pharmacy rather than manufactured by a licensed drug manufacturer and approved as a finished product by the FDA — lack the clinical evidence and regulatory status that Cigna requires for coverage. This is distinct from the status of FDA-approved branded semaglutide products; Cigna is specifically targeting the compounded version. This denial type is applied consistently by most large commercial insurers to compounded GLP-1 preparations and is among the most difficult denial types to overturn on purely clinical grounds. However, an appeal is still legally available and is worth pursuing.

## Why This Is Appealable

The appeal argument centers on (1) medical necessity — demonstrating that the patient cannot access the branded FDA-approved equivalent due to a documented shortage, formulary barrier, or clinical contraindication — and (2) challenging the application of the "experimental" label by citing the well-established clinical evidence base for the semaglutide molecule itself, as recognized by major guideline-issuing organizations (e.g., the American Diabetes Association, the Obesity Society, and relevant endocrinology societies). The appeal does not assert that the compound equals the branded product; it asserts that the denial harms a patient who has no available alternative.

## The Federal Appeal Framework

• Internal appeal: File under ERISA Section 503 (employer plans) or ACA Section 2719 (individual/marketplace plans) within the deadline on your denial letter. Include a comprehensive clinical record and a prescriber letter addressing the experimental-designation basis directly.
• External review: Under ACA Section 2719, you may request independent external review after exhausting internal appeals — generally within four months of the final denial. External reviewers must apply "generally accepted standards of medical practice" and are not bound by Cigna's internal experimental/investigational policies.
• Expedited review: Request if delay poses imminent clinical risk.

## Documentation to Gather

• Diagnosis and severity documentation: Chart notes confirming the clinical diagnosis (e.g., type 2 diabetes, obesity with comorbidities), relevant lab history, and severity indicators justifying pharmacological intervention.
• Prior treatment history: A timeline of all prior pharmacological treatments tried, with dates, duration, and outcomes — establishing that the patient has exhausted or cannot tolerate available alternatives.
• Branded product access barrier: Documentation of FDA shortage status (FDA drug shortage database entry), formulary exclusion, or documented clinical reason that the branded FDA-approved formulation is not appropriate for this specific patient.
• Prescriber medical-necessity letter: Addressing the experimental denial basis, citing the recognized clinical guideline organizations that endorse semaglutide's mechanism in the patient's condition, and explaining why compounded access is medically necessary in the absence of a viable alternative.
• Compounding pharmacy accreditation: If available, PCAB or state-board accreditation of the dispensing pharmacy.

## Criteria-Mapping Structure

Obtain Cigna's coverage policy for experimental/investigational drugs and its specific policy on compounded medications:

| Cigna Experimental Criterion | Appeal Response | |---|---| | No FDA approval for this formulation | Acknowledge compound status; assert shortage/access barrier | | Insufficient clinical evidence | Reference major guideline organization endorsement of semaglutide for this indication | | Available FDA-approved alternative | Document formulary exclusion, shortage, or clinical contraindication to branded product |

Also verify the current FDA shortage status of the relevant branded semaglutide product at the time of prescribing — this is often a pivotal piece of evidence in these appeals.